Hypertension and edema

Report Year

Trial Code

Trial Title

Clinicaltrials.gov

EudraCTno.

Source

2000

BUX 9501 DK

Bumetanide controlled release capsules in congestive heart failure

N/A

N/A

Summary

Report

Active Substance

bumetanide

LEO Pharma Product

Burinex®

Formulation

tablet & capsule

Trial Phase

2

Population

adults

1999

CE 9401 DK

Efficacy and safety of Centyl® with potassium chloride (bendroflumethiazide) 1.25 mg and 2.5 mg compared to Renitec® (enalapril) 10 mg and Norvasc® (amlodipine) 5 mg in patients with mild to moderate primary

N/A

N/A

Summary

Report

Active Substance

bendroflumethiazide + potassium chloride

LEO Pharma Product

Centryl® K

Formulation

tablet

Trial Phase

3

Population

adults

1999

BU 9202 UK / GP 97

Comparative effects of bumetanide plus captopril in patients with congestive cardiac failure with long-term follow-up for up to two years

N/A

N/A

Summary

Report

Active Substance

bumetanide

LEO Pharma Product

Burinex®

Formulation

tablet

Trial Phase

4

Population

adults

1997

BUFUL NL

A comparative study of the influence of bumetanide and furosemide on the lipidprofile in patients with essential hypertension

N/A

N/A

Summary

Report

Active Substance

bumetanide

LEO Pharma Product

Burinex®

Formulation

tablet

Trial Phase

3

Population

adults

1997

CE 9402 DK

Comparison of Centyl® + KCI 1,25 mg, 2,5 mg(bendroflumethiazid) and Corodil® 10mg (enalapril) in niddm patients with mild to moderate hypertension

N/A

N/A

Summary

Report

Active Substance

bendroflumethiazide + potassium chloride

LEO Pharma Product

Centryl® K & Centryl® K Mite

Formulation

tablet

Trial Phase

3

Population

adults

1992

BX 0309

A comparison of the bioavailability of bumetanide following oral administration as a combined formulation with amiloride and comparison of this with a similar combined formulation of frusemide

N/A

N/A

Summary

Report

Active Substance

bumetanide + amiloride hydrochloride

LEO Pharma Product

N/A

Formulation

tablet

Trial Phase

2

Population

adults

1991

BX 0290

Ingenol mebutate gel, 0.015% repeat use for multiple actinic keratoses on face and scalp

N/A

N/A

Summary

Report

Active Substance

bumetanide + amiloride hydrochloride

LEO Pharma Product

N/A

Formulation

tablet

Trial Phase

2

Population

adults

Cookies auf dieser Seite

LEO Pharma verwendet Cookies, um Ihr Online-Erlebnis zu optimieren und um anonyme statistische Daten zur Nutzung der Website zu erhalten. Sie können hier sehen, welche Cookies wir verwenden, was diese bewirken und wie Sie sie deaktivieren können COOKIES. Indem Sie unsere Website nutzen, stimmen Sie der Verwendung von Cookies zu. Indem Sie diese Meldung bestätigen, erklären Sie sich damit einverstanden, dass wir Cookies gemäß unseren Cookie-Richtlinien auf diesem Gerät verwenden, sofern Sie diese nicht deaktiviert haben.